Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PAH patients may ditch frequent inhalers for a Once-Daily pill

NCT ID NCT07356375

Symptom relief Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 32 adults with pulmonary arterial hypertension (PAH) whose doctors decide to switch them from inhaled iloprost (taken several times a day) to oral selexipag (a pill). Researchers will use questionnaires to see if the switch improves quality of life, treatment satisfaction, and how well patients stick with their medication. A comparison group staying on iloprost will also be observed. No experimental treatments are involved—all care is routine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Selexipag (oral medication)
What this could lead to
If successful, this study could show that switching to a once-daily pill improves daily life and makes it easier for people with PAH to stick with their treatment.
What could go wrong
This is a small, observational study (32 people) that does not test a new drug—it simply observes a routine switch. Results may not apply to everyone with PAH.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with a confirmed diagnosis of pulmonary arterial hypertension (PAH, Group 1) who are receiving inhaled iloprost as part of routine clinical care at a specialized referral center. Eligible patients are those for whom the treating physician has decided, based on clinical judgment, to transition therapy from inhaled iloprost to oral selexipag. Participants are followed prospectively to assess patient-reported outcomes, treatment satisfaction, adherence, and safety associated with this treatment transition. All clinical decisions are made independently of study participation, and no study-mandated interventions are performed.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 18 years or older. * Confirmed diagnosis of pulmonary arterial hypertension (PAH, Group 1) by right heart catheterization. * Current treatment with inhaled iloprost as part of routine clinical care. * Clinical decision by the treating physician to transition from inhaled iloprost to oral selexipag. * Ability to understand and complete patient-reported outcome questionnaires. * Provision of written informed consent. Exclusion Criteria * Significant cognitive impairment or sensory deficits that prevent completion of study questionnaires. * Unstable or decompensated comorbid conditions that may interfere with treatment adherence or study participation. * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension (PAH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension (PAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.